ROR1 and breast carcinoma: Additionally, treatment of HER2+ breast cancer cells (patient-derived, HCC1954 and MCF7-HER2+) with the HER2-targeting monoclonal antibody trastuzumab (T-DM1), led to a dramatic increase in ROR1 expression.